Related content

Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies

By Peluso Rosario  

Clinical Rheumatology, Vol. 32, Iss. 6, 2013-06 ,pp. : 743-753

Springer Publishing Company

Access to resources Recommend Favorite

Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy

By Iannone F   Fanizzi R   Scioscia C   Anelli MG   Lapadula G  

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 1, 2013-01 ,pp. : 41-44

Informa Healthcare

Access to resources Recommend Favorite

ELISPOT-IFN-γ assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-α treatment

By Girlanda Stefania   Mantegani Paola   Baldissera Elena   Aiello Patrizia   Ratti Manuela   Sabbadini Maria   Fortis Claudio  

Clinical Rheumatology, Vol. 29, Iss. 10, 2010-10 ,pp. : 1135-1141

Springer Publishing Company

Access to resources Recommend Favorite

Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?

By Tektonidou Maria   Skopouli Fotini  

Clinical Rheumatology, Vol. 27, Iss. 4, 2008-04 ,pp. : 541-542

Springer Publishing Company

Access to resources Recommend Favorite

Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

By Li Sophia   Kaur Primal   Chan Virginia   Berney Steven  

Clinical Rheumatology, Vol. 28, Iss. 7, 2009-07 ,pp. : 787-791

Springer Publishing Company

Access to resources Recommend Favorite